Medicis Pharmaceutical’s subsidiary Medicis Technologies has received US Food and Drug Administration (FDA) clearance for its second generation LipoSonix system, designed for non-invasive waist circumference reduction.

The LipoSonix system uses high-intensity focused ultrasound energy to disrupt subcutaneous adipose tissue.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The approval is backed by a multicentre, randomised, sham-controlled and blind study, which showed that treatment with the LipoSonix system was superior to a sham control in reducing waist circumference.

Clinical studies conducted by Medicis Technologies demonstrated an average waist circumference reduction of approximately 2.6cm after a single treatment with the LipoSonix system.

The first generation LipoSonix system is currently available in Canada, the European Union and Japan.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact